NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Neurology

• Publication date

  2005-09-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1212/01.wnl.0000171978.70849.c5PMID 16157899
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neurotrophic factors and their receptors in axonal regeneration and functional recovery after peripheral nerve injury

  2003cited by this paper
• The neurofilament middle molecular mass subunit carboxyl-terminal tail domains is essential for the radial growth and cytoskeletal architecture of axons but not for regulating neurofilament transport rate

  2003cited by this paper
• Evidence for impaired axonal regeneration in PMP22 duplication: studies in nerve xenografts

  2003cited by this paper
• Platelet‐derived growth factor‐b expression induced after rat peripheral nerve injuries

  2002cited by this paper
• Proteins of peripheral myelin are associated with glycosphingolipid/cholesterol‐enriched membranes

  2002cited by this paper
• Neurotrophin-3-mediated regeneration and recovery of proprioception following dorsal rhizotomy.

  2002cited by this paper
• Schwann cells as regulators of nerve development.

  2002cited by this paper
• The Neurotrophin Receptor p75NTR as a Positive Modulator of Myelination

  2002cited by this paper
• Inaugural Article: Neurotrophins are key mediators of the myelination program in the peripheral nervous system

  2001cited by this paper
• Regulation of Schwann cell proliferation and apoptosis in PMP22-deficient mice and mouse models of Charcot-Marie-Tooth disease type 1A.

  2001cited by this paper
• Nerve growth factor and neurotrophin-3 affect functional recovery following peripheral nerve injury differently

  2001cited by this paper
• Platelet‐derived growth factor‐BB supports the survival of cultured rat schwann cell precursors in synergy with neurotrophin‐3

  2000cited by this paper
• Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system.

  2000cited by this paper
• Developing Schwann Cells Acquire the Ability to Survive without Axons by Establishing an Autocrine Circuit Involving Insulin-Like Growth Factor, Neurotrophin-3, and Platelet-Derived Growth Factor-BB

  1999cited by this paper
• Effects of PMP22 duplication and deletions on the axonal cytoskeleton

  1999cited by this paper
• Expression of Trk receptors in the developing mouse trigeminal ganglion: in vivo evidence for NT-3 activation of TrkA and TrkB in addition to TrkC.

  1999cited by this paper
• A Role for Insulin-Like Growth Factor-I in the Regulation of Schwann Cell Survival

  1999cited by this paper
• Schwann cells and their precursors emerge as major regulators of nerve development.

  1999cited by this paper
• Neurotrophin Modulation of the Monosynaptic Reflex after Peripheral Nerve Transection

  1999cited by this paper
• Peripheral nerve regeneration and neurotrophic factors

  1999cited by this paper
• Abnormal Schwann cell-axon interactions in CMT neuropathies. The effects of mutant Schwann cells on the axonal cytoskeleton and regeneration-associated myelination.

  1999cited by this paper
• A novel PMP22 point mutation causing HNPP phenotype

  1998cited by this paper
• Effect of sciatic nerve crush on local and target tissue production of neurotrophin-3 transcripts in rats.

  1998cited by this paper
• Chronically denervated rat schwann cells respond to GGF in vitro

  1998cited by this paper
• Expression of insulin‐like growth factors and corresponding binding proteins (IGFBP 1–6) in rat spinal cord and peripheral nerve after axonal injuries

  1998cited by this paper
• Fate of Schwann Cells in CMT1A and HNPP: Evidence for Apoptosis

  1998cited by this paper
• Measuring vibration threshold with a graduated tuning fork in normal aging and in patients with polyneuropathy

  1998cited by this paper
• Schwann cells, neurotrophic factors, and peripheral nerve regeneration

  1998cited by this paper
• A Morphological Study of Schwann Cells and Axonal Regeneration in Chronically Transected Human Peripheral Nerves

  1998cited by this paper
• Abnormalities in the axonal cytoskeleton induced by a connexin32 mutation in nerve xenografts

  1998cited by this paper
• Neurotrophin-3-like immunoreactivity and Trk C expression in human spinal motoneurones in amyotrophic lateral sclerosis.

  1997cited by this paper
• Neurotrophin-3 Administration Attenuates Deficits of Pyridoxine-Induced Large-Fiber Sensory Neuropathy

  1997cited by this paper
• Neurotrophin‐3 Delivered Locally via Fibronectin Mats Enhances Peripheral Nerve Regeneration

  1997cited by this paper
• The cellular and molecular basis of peripheral nerve regeneration

  1997cited by this paper
• Schwann cell apoptosis at developing neuromuscular junctions is regulated by glial growth factor

  1996cited by this paper
• Therapeutic potential of the neurotrophins and neurotrophin-CNTF combinations in peripheral neuropathies and motor neuron diseases.

  1996cited by this paper
• Cell death in the Schwann cell lineage and its regulation by neuregulin.

  1996cited by this paper
• Characterization of Insulin‐Like Growth Factor‐I and Its Receptor and Binding Proteins in Transected Nerves and Cultured Schwann Cells

  1996cited by this paper
• Neurotrophin‐3 reverses experimental cisplatin‐induced peripheral sensory neuropathy

  1995cited by this paper
• Nerve growth factor and neurotrophin-3 enhance neurite outgrowth and up-regulate the levels of messenger RNA for growth-associated protein GAP-43 and T alpha 1 alpha-tubulin in cultured adult rat sensory neurones.

  1995cited by this paper
• Differential spatio-temporal expression of the insulin-like growth factor genes in regenerating sciatic nerve.

  1995cited by this paper
• Variables influencing neuropathic endpoints

  1995cited by this paper
• The Trk family of neurotrophin receptors.

  1994cited by this paper
• Reciprocal Schwann cell-axon interactions.

  1993cited by this paper
• Differential expression of mRNAs for neurotrophins and their receptors after axotomy of the sciatic nerve

  1993cited by this paper
• Platelet‐derived growth factor and regulation of schwann cell proliferation in vivo

  1992cited by this paper
• Synthesis and localization of ciliary neurotrophic factor in the sciatic nerve of the adult rat after lesion and during regeneration

  1992cited by this paper
• Alterations in slow transport kinetics induced by estramustine phosphate, an agent binding to microtubule‐associated proteins

  1992cited by this paper
• Detection of brain-derived neurotrophic factor-like activity in fibroblasts and Schwann cells: inhibition by antibodies to NGF.

  1991cited by this paper
• Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a). The HMSN Collaborative Research Group.

  1991cited by this paper
• DNA duplication associated with Charcot-Marie-Tooth disease type 1A.

  1991cited by this paper
• Measuring Vibration Sensations With Graduated Tuning Fork: Simple and Reliable Means to Detect Diabetic Patients at Risk of Neuropathic Foot Ulceration

  1990cited by this paper
• REGENERATION IN THE PERIPHERAL NERVOUS SYSTEM

  1989cited by this paper
• Changes of nerve growth factor synthesis in nonneuronal cells in response to sciatic nerve transection

  1987cited by this paper
• REGENERATION IN CELLULAR AND ACELLULAR AUTOGRAFTS IN THE PERIPHERAL NERVOUS SYSTEM

  1986cited by this paper
• Human diabetic endoneurial sorbitol, fructose, and myo‐inositol related to sural nerve morphometry

  1980cited by this paper
• Studies of Schwann cell proliferation. I. An analysis in tissue culture of proliferation during development, Wallerian degeneration, and direct injury

  1980cited by this paper
• The nature of myelinated nerve fiber degeneration in dominantly inherited hypertrophic neuropathy.

  1974cited by this paper

• AAVrh74.tMCK.NT-3 Surrogate Gene Therapy in a Mouse Model of CMT2A.

  2026cites this paper
• The Application of Stem Cells and Exosomes in Promoting Nerve Conduits for Peripheral Nerve Repair

  2025cites this paper
• PMP22-Related Neuropathies: A Systematic Review

  2025cites this paper
• AAV1.NT3 gene therapy mitigates the severity of autoimmune encephalomyelitis in the mouse model for multiple sclerosis

  2025cites this paper
• Pathologic and Therapeutic Schwann Cells

  2025cites this paper
• Les nombreuses pistes thérapeutiques de la maladie de Charcot-Marie-Tooth

  2025cites this paper
• Analgesic Activity of the Low Molecular Weight Neurotrophin-3 Dipeptide Mimetic GTS-301

  2025cites this paper
• Biomarkers and Novel Therapies of Diabetic Neuropathy: An Updated Review.

  2024cites this paper
• AAV1.tMCK.NT-3 gene therapy improves phenotype in Sh3tc2−/− mouse model of Charcot–Marie–Tooth Type 4C

  2024cites this paper
• Charcot‐Marie‐Tooth disease in children

  2024cites this paper
• ACD856, a novel positive allosteric modulator of Trk receptors, single ascending doses in healthy subjects: Safety and pharmacokinetics

  2024cites this paper
• Review of cellular therapies provides new insights into the potential treatment of diverse neurologic diseases in horses and dogs.

  2024cites this paper
• Positive Allosteric Modulators of Trk Receptors for the Treatment of Alzheimer’s Disease

  2024cites this paper
• Hereditary neuropathy.

  2023cites this paper
• Current Advances in Gene Therapies of Genetic Auditory Neuropathy Spectrum Disorder

  2023cites this paper
• Targeting muscle to treat Charcot-Marie-Tooth disease

  2023cites this paper
• Neurotrophin-3 promotes peripheral nerve regeneration by maintaining a repair state of Schwann cells after chronic denervation via the TrkC/ERK/c-Jun pathway

  2023cites this paper
• Growth factors and molecular-driven plasticity in neurological systems.

  2023cites this paper
• Vascular and Neural Response to Focal Vibration, Sensory Feedback, and Piezo Ion Channel Signaling

  2023cites this paper
• The Current State of Charcot–Marie–Tooth Disease Treatment

  2023cites this paper
• Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects

  2023cites this paper
• Gene therapy and other novel treatment approaches for Charcot-Marie-Tooth disease.

  2023cites this paper
• Effects of Whole-Body Vibration and Manually Assisted Locomotor Therapy on Neurotrophin-3 Expression and Microglia/Macrophage Mobilization Following Thoracic Spinal Cord Injury in Rats

  2023cites this paper
• Charcot–Marie–Tooth neuropathies: Current gene therapy advances and the route toward translation

  2023cites this paper
• Electroceutical approach ameliorates intracellular PMP22 aggregation and promotes pro-myelinating pathways in a CMT1A in vitro model.

  2022cites this paper
• CMT1A current gene therapy approaches and promising biomarkers

  2022cites this paper
• Electrospun fiber-mediated delivery of neurotrophin-3 mRNA for neural tissue engineering applications.

  2022cites this paper
• A translatable RNAi-driven gene therapy silences PMP22/Pmp22 genes and improves neuropathy in CMT1A mice

  2022cites this paper
• Treatment of Charcot-Marie-Tooth neuropathies.

  2022cites this paper
• Clinical and Genetic Survey for Charcot-Marie-Tooth Neuropathy Based on the Findings in Turkey, a Country with a High Rate of Consanguineous Marriages

  2022cites this paper
• Delayed viral vector mediated delivery of neurotrophin-3 improves skilled hindlimb function and stability after thoracic contusion

  2022cites this paper
• Pathology of the peripheral neuropathy Charcot-Marie-Tooth disease type 4H in Holstein Friesian cattle with a splice site mutation in FGD4

  2022cites this paper
• Fully Implantable Neural Stimulator with Variable Parameters

  2022cites this paper
• Genetic approaches and pathogenic pathways in the clinical management of Charcot-Marie-Tooth disease

  2022cites this paper
• Challenges in Treating Charcot-Marie-Tooth Disease and Related Neuropathies: Current Management and Future Perspectives

  2021cites this paper
• AAV1.NT-3 gene therapy in a CMT2D model: phenotypic improvements in GarsP278KY/+ mice

  2021cites this paper
• AAV1.NT-3 gene therapy for X-linked Charcot–Marie–Tooth neuropathy type 1

  2021cites this paper
• The Complex Clinical and Genetic Landscape of Hereditary Peripheral Neuropathy.

  2021cites this paper
• Mechanisms and Treatments in Demyelinating CMT

  2021cites this paper
• Emerging Therapies for Charcot-Marie-Tooth Inherited Neuropathies

  2021influential citation
• Peripherally delivered Adeno-associated viral vectors for spinal cord injury repair.

  2021cites this paper
• Effects of early crush on aging wild type and Connexin 32 knockout mice: Evidence for a neuroprotective state in CMT1X mouse nerve

  2021cites this paper
• Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis

  2021cites this paper
• Therapeutic Development in Charcot Marie Tooth Type 1 Disease

  2021cites this paper
• Effect of malignant growth and chronic neurogenic pain on neurotrophin levels in rat brain

  2021cites this paper
• The Roles of Neurotrophins in Traumatic Brain Injury

  2021cites this paper
• Pain Phenotypes in Rare Musculoskeletal and Neuromuscular Diseases.

  2021cites this paper
• Updated review of therapeutic strategies for Charcot-Marie-Tooth disease and related neuropathies

  2021cites this paper
• Animal Models as a Tool to Design Therapeutical Strategies for CMT-like Hereditary Neuropathies

  2021cites this paper
• Neurotrophin-3 attenuates human peripheral blood T cell and monocyte activation status and cytokine production post stroke.

  2021cites this paper
• Abstract. Glycoprotein non-metastatic melanoma protein B (GPNMB) exerts neuroprotective effects on amyotrophic lateral sclerosis and cerebral ischemia reperfusion

  2020cites this paper
• Gene Therapy Options as New Treatment for Inherited Peripheral Neuropathy

  2020cites this paper
• Treating PMP22 gene duplication-related Charcot-Marie-Tooth disease: The past, the present and the future.

  2020cites this paper
• Gene specific therapies – the next therapeutic milestone in neurology

  2020cites this paper
• Identification of Candidate Genes Associated with Charcot-Marie-Tooth Disease by Network and Pathway Analysis

  2020cites this paper
• Neurotrophin‐3 stimulates stem Leydig cell proliferation during regeneration in rats

  2020cites this paper
• New Therapeutics Options for Pediatric Neuromuscular Disorders

  2020cites this paper
• Cerebrolysin enhances spinal cord conduction and reduces blood-spinal cord barrier breakdown, edema formation, immediate early gene expression and cord pathology after injury.

  2020cites this paper
• New Evidence for Secondary Axonal Degeneration in Demyelinating Neuropathies.

  2020cites this paper
• Gene therapy to promote regeneration in Charcot-Marie-Tooth disease.

  2020cites this paper
• Growth factors-based therapeutic strategies and their underlying signaling mechanisms for peripheral nerve regeneration

  2020cites this paper
• Altered expression of glycoprotein non-metastatic melanoma protein B in the distal sciatic nerve following injury

  2020cites this paper
• Inherited Neuropathies

  2019cites this paper
• Low-intensity pulsed ultrasound for regenerating peripheral nerves: potential for penile nerve

  2019cites this paper
• Therapeutic Potential of Neurotrophins for Repair After Brain Injury: A Helping Hand From Biomaterials

  2019cites this paper
• Disease Modeling and Therapeutic Strategies in CMT2A: State of the Art

  2019cites this paper
• Rodent models with expression of PMP22: Relevance to dysmyelinating CMT and HNPP.

  2019cites this paper
• BDNF, NT-3 and Trk receptor agonist monoclonal antibodies promote neuron survival, neurite extension, and synapse restoration in rat cochlea ex vivo models relevant for hidden hearing loss

  2019cites this paper
• miR-381 Attenuates Peripheral Neuropathic Phenotype Caused by Overexpression of PMP22

  2019cites this paper
• Charcot-Marie-Tooth: From Molecules to Therapy

  2019cites this paper
• Descending motor circuitry required for NT-3 mediated locomotor recovery after spinal cord injury in mice

  2019cites this paper
• Corticospinal neuroplasticity and sensorimotor recovery in rats treated by infusion of neurotrophin-3 into disabled forelimb muscles started 24 h after stroke

  2018cites this paper
• Identifying Genetic Modifiers in Charcot-Marie-Tooth Disease Type 1A

  2018cites this paper
• Charcot–Marie–Tooth Disease

  2018cites this paper
• Application of differentiated human tonsil–derived stem cells to trembler‐J mice

  2018cites this paper
• Stroke recovery in rats after 24h-delayed, intramuscular neurotrophin-3 infusion

  2018cites this paper
• Challenges in modelling the Charcot-Marie-Tooth neuropathies for therapy development

  2018cites this paper
• Efficacy of exogenous pyruvate in TremblerJ mouse model of Charcot‐Marie‐Tooth neuropathy

  2018cites this paper
• Stroke Recovery in Rats after 24‐Hour–Delayed Intramuscular Neurotrophin‐3 Infusion

  2018cites this paper
• Gene therapy approach on Charcot-Marie-Tooth type 1A rats

  2018cites this paper
• Neuromuscular Disorders

  2018cites this paper
• Cell transplantation strategies for acquired and inherited disorders of peripheral myelin

  2018cites this paper
• AAV1.NT-3 gene therapy increases muscle fiber diameter through activation of mTOR pathway and metabolic remodeling in a CMT mouse model

  2018cites this paper
• Subcutaneous Neurotrophin-3 infusion induces corticospinal neuroplasticity and improvements in dexterity and walking in elderly rats after large cortical stroke

  2018cites this paper
• Targeting Neurotrophins to Specific Populations of Neurons: NGF, BDNF, and NT-3 and Their Relevance for Treatment of Spinal Cord Injury

  2017cites this paper
• Treating pediatric neuromuscular disorders: The future is now

  2017cites this paper
• Low-intensity pulsed ultrasound accelerates nerve regeneration following inferior alveolar nerve transection in rats.

  2016cites this paper
• A Review of X-linked Charcot-Marie-Tooth Disease

  2016cites this paper
• Intramuscular Neurotrophin-3 normalizes low threshold spinal reflexes, reduces spasms and improves mobility after bilateral corticospinal tract injury in rats

  2016influential citation
• Rehabilitation issues in Charcot-Marie-Tooth disease

  2016cites this paper
• An Update ON Charcot–Marie–Tooth Diseases

  2016cites this paper
• Recent advances in the genetic neuropathies.

  2016cites this paper
• Promoting peripheral myelin repair.

  2016cites this paper
• Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot–Marie–Tooth Disease

  2016cites this paper
• Synergetic effects of ciliary neurotrophic factor and olfactory ensheathing cells on optic nerve reparation (complete translation)

  2016cites this paper
• Charcot-Marie-Tooth type 1A disease from patient to laboratory.

  2015cites this paper
• Therapeutic options in Charcot–Marie–Tooth diseases

  2015cites this paper
• AAV1.NT-3 gene therapy attenuates spontaneous autoimmune peripheral polyneuropathy

  2015cites this paper
• Hereditary motor and sensory neuropathies: Understanding molecular pathogenesis could lead to future treatment strategies.

  2015cites this paper
• Distribución mutacional y correlación genotipo-fenotipo del síndrome de Charcot-Marie-Tooth en la Comunidad Valenciana.

  2015cites this paper